Drug search by name

Gadoxetate Intravenous and Nephrogenic systemic fibrosis

Result of checking the interaction of drug Gadoxetate Intravenous and disease Nephrogenic systemic fibrosis for safety when used together.

Check result:

Gadoxetate Intravenous <> Nephrogenic systemic fibrosis

Relevance: 23.07.2019 Reviewer: Shkutko P.M., M.D., in

When checking interaction based on authoritative sources Drugs.com, Rxlist.com, Webmd.com, Medscape.com there are contraindications or side effects that may cause harm or increase the negative effect from drug use in presence of concomitant diseases.

Consumer:

Gadolinium based contrast agents (GBCAs) increase the risk for nephrogenic systemic fibrosis (NSF) among patients with impaired elimination of the drugs. Use of these agents should be avoided in these patients unless the diagnostic information is essential and unavailable with non- contrasted MRI or other diagnostic modalities. NSF may result in fatal or debilitating fibrosis affecting the skin, muscle and internal organs. The risk of NSF appears to be higher in patients with chronic severe renal disease and patients with acute kidney injury. Patients should be screened for acute renal injury and other conditions that might affect renal function such as age >60 years old, hypertension, and diabetes.

Gadoxetate Intravenous

Generic Name: gadoxetate disodium

Brand Name: Eovist

Synonyms: Gadoxetate

What is Gadoxetate Intravenous?